Cost-Effectiveness of a Pediatric Dengue Vaccine
Daniel N.C. Wang, Donald S. Shepard*, Duane J. Gubler, Jose A. Suaya, Martin I. Meltzer, Michael B. Nathan, Richard T. Mahoney, Scott B. Halstead
Schneider Institute for Health Policy, Heller School, Room G19, Mail Stop 035, Brandeis University, Waltham, USA. Tel: +1-781-736-3975; Fax: +1-781-736-3928, E-mail:
To ascertain the economic feasibility of a pediatric tetravalent dengue vaccine, we developed and calibrated a cost-effectiveness model of vaccinating children at 15 months in Southeast (SE) Asia using a societal perspective. We assumed that full immunization would require two doses at prices of US$ 0.50 and US$ 10 per dose in the public and private sectors, respectively. The gross cost per 1000 population (of all ages) of the vaccination program would be US$ 154. Due to projected savings in dengue treatment, the net cost per capita would be only US$ 17 (89% below the gross cost). The cost per disability adjusted life year (DALY) saved by a pediatric vaccine would be US$ 50,making the potential vaccine highly cost-effective. Eventually, vaccination may be able to replace environmental control as a strategy for dengue prevention and be cost saving. 
Vaccine ปี 2547, March ปีที่: 22 ฉบับที่ 9-10 หน้า 1275-1280
cost-effectiveness, Cost, DALY, Dengue, Developing countries, Disability-adjusted life year, Southeast Asia, Vaccination, Vaccine